ACR 2026 RheumNow ILD Topic Compilation c Save
Real World of SARD ILD
What are our goals, really, in ILD
RA-ILD and Lung Cancer
Disease Activity in RA-ILD Worse Survival, Unclear Lung Progression
Transcription
This is an ACR 2026 podcast coming to you from ACR in Orlando. Hope you enjoy it.
This Room Now podcast is brought to you with support from Boehringer Ingelheim. Boehringer Ingelheim is committed to advancing research in rheumatology through ongoing work in progressive pulmonary fibrosis, interstitial lung disease, and systemic autoimmune rheumatic diseases, including systemic sclerosis, myositis, and beyond. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies in areas of high unmet medical need. Boehringer Ingelheim is proud to support RheumNow and the rheumatology community. Thank you for listening.
Hello, everyone. I'm Richard Conway from Dublin, Ireland reporting from ACR twenty twenty six for RheumNow. I'm here to talk to you today about an interesting poster from Sunday's poster session. This was abstract number four seventy. It was by Matute Gallardo and colleagues from Spain.
This was titled Treatment Patterns of Oral ILD Compared to Other Autoimmune ILDs. I'm calling it the real world of SARD ILD treatment. And I guess people are going to think I'm banging on about the same thing endlessly. But this interested me because it shows what rheumatologists in Spain, not in The US, but in Spain, do in practice and how that contrasts with the ACR, SARD, ILD guidelines. So just a way of background, the ACR guidelines recommend for rheumatoid arthritis related interstitial lung disease three first line therapies, but in order of preference, mycophenolate mofetil first, azathioprine second, rituximab third.
So these authors reported from their patient population about how these patients were actually treated in clinical practice. So they had patients with oral LD and patients with other rheumatic diseases associated with ILD. They had eighty five patients in total, thirty eight of those had rheumatoid arthritis related interstitial lung disease. So the non rheumatoid arthritis patients first sort of the usual stuff, systemic sclerosis, IPAF, some other autoimmune diseases associated with lung disease. And in that group, largely speaking, mycophenolate mofetol was the preferred option being seen for the various indications somewhere between seventy five percent, eighty five percent of patients were on mycophenolate.
So that kind of matches both the ACR guidelines for those diseases and matches what I do in clinical practice, and I think most rheumatologists do. But where the contrast came was with ORA ILD. So again, remember, ACR guidelines, mycophenolate number one, azatyper number two, rituximab number three. So first thing, I was delighted to see this. Ninety five percent of those RA patients were on methotrexate despite the fact that they had ILD.
So obviously there is confidence in the data that says it is safe and if anything may be beneficial to some extent in RAILD. And then when they got down into the advanced therapies, what they found, so patients on mycophenolate mofetil, zero. Patients on azathioprine, zero. Most commonly used medication, abatacept. Twenty six percent of patients on that.
Sixteen percent on rituximab, sixteen percent on tocilizumab, sixteen percent on nothing other than the methotrexate, which can be reasonable. And then the remainder were on a variety of JAK inhibitors and TNF inhibitors. So why do I like this abstract? I think, like anybody, I like when it supports your own clinical practice. And it seems that all those doubting thoughts that the ACR guidelines generate of, am I actually way out of sync with everyone is not true.
And that's in reality, most rheumatologists are managing rheumatoid arthritis related interstitial lung disease as I manage it, which is treating the rheumatoid arthritis with our best rheumatoid arthritis medications. And that is where we go. So I've been Richard Conway. Follow me on Twitter at RichardPAconway for more from ACR twenty twenty six from me, and check out RheumNow for all the best ACR twenty twenty six coverage.
Hello. My name is Elena Jerns. I'm reporting live from Orlando, Florida, ACR twenty twenty six. I want to talk to you about the session on autoimmune ILD that I saw today. It was fantastic.
It was delivered by a pulmonologist, Doctor. Zaman from Cedars Sinai and Doctor. Castellino from MassGen Hospital. They talked about a few things, what we really want from autoimmune ILD, and I just really loved how they delivered that. First, they emphasized what physicians treating autoimmune ILD really want from the drugs and from the studies.
First, many of the new drugs, many of the recent new drugs are being advertised that they're great because they slow down the rate of decline of ILD. I mean, is great. Nobody argues about that. But the excitement of that slowing down really comes from the data on idiopathic pulmonary fibrosis, but the disease is really relentless and, like, we expect it to progress. But the goals in SARDA ILD can be very different.
We actually want SARDA ILD to improve. We don't want merely stabilization or attenuation of the lung function decline. The reason for that is a ton of SARD ILD is inflammatory. We can argue that all of it is inflammatory because we have a SARD, right? Something like myositis ILD, for example.
The patient may decline fast and then stabilize, usually with the help of steroids, but we would strive to bring back the lung function with immunosuppressants or maybe a combination of drugs that include immunosuppressants. The session even presented some data that fibrotic looking ILD, like our radio ILD with usual interstitial pneumonia pattern, might at the very least stabilize with immunosuppression, even though oftentimes we hear that, Oh, these patients just need anti fibrotic. They probably need immunosuppressants as well. So takeaway point for that is that we can and we should strive for improvement in SART ILD. The session also emphasized the gap in autoimmune ILD studies, and I think that's a big one.
Many medications, especially the newer ones, have focused on progressive pulmonary fibrosis, but SARD ILD might not necessarily fall into that, at least not in the timeframe that a lot of those studies use as inclusion criteria. So we don't always know if the results of those studies are applicable to our patients with SAARD ILD. Also the outcomes that those studies have focused on really have been reduction in FVC decline, but as we talked about, some SAARDA ILD will not necessarily have that FVC decline. It might not be as relevant, you know, and also SAARDA ILD may not follow a linear course like a lot of patients with idiopathic pulmonary fibrosis can. So again, not super relevant.
And we are often left confused about whether to treat SAARD ILD that is not progressive, and what we should hope for. We don't really often know that from the results of the studies. And I think that lecture emphasized that we need more studies that enroll all comers of SARDA ILD, and also with outcomes that really focus on many aspects of the disease, and also the ILD of the disease and patient outcomes, because sometimes we can help the patient with those even if we don't necessarily improve the numbers on pulmonary function tests. But we need to prove that. So my takeaway point is that design studies of ILD that include non progressive fibrosis and power for improvement.
And the third takeaway point is that rheumatologists should be actively involved in SARD ILD management. Our patients with SARD ILD have many aspects to their disease that we need to balance the treatment for each of them against others and also against the risk for infection. We have so many drugs luckily that can help with many manifestations of that disease, but sometimes one that is more effective for one may not be as effective for others, so we still end up combining them. And this is complicated and it requires careful rheumatological expertise, so we should not leave the SARD ILD to the pulmonologist even though they're of course wonderful and many of them can treat SARD ILD just fine, but SARD ILD is more than just ILD. In SARD, in rheumatology, we need to treat the whole patient and all the extrapulmonary manifestations.
And we as rheumatologists should be well versed in drugs that can help the whole patient while helping the lungs. I guess a takeaway point is that SARTA LD is a team sport. If we were to go with soccer analogy, which I don't play soccer at all even, but I would say that a rheumatologist may take more the role of the offense with kind of just putting all those drugs out there, and the pulmonologist may be more like a goalie and kind of making sure that the lungs don't fall through the cracks. Thank you.
Hello, everyone. I'm Richard Conway from Dublin, Ireland. I'm reporting from ACR twenty twenty six for RheumNow. I'm here to talk to you today about an abstract that was presented at Monday's abstract session. And this is an ILD abstract, but I think maybe some ILD people will not have encountered it as was presented in the epidemiology and public health abstract session and not the rheumatoid abstract session.
This is by Kim et al from Korea. And the proper title of this is Lung Cancer Risk in RA and RA A risk analysis. I've called it RA A, and lung cancer. I think that's, does what it says on the tin, that's what it's about. This is a single center cohort, relatively large numbers of patients, however, six sixty four rheumatoid arthritis patients, two thirty of those had ILD, which is a lot.
That is more than a third of their patients. So it seems ILD is quite common in Korea. So that was one of the things they were looking at. And the other thing was lung cancer. Lung cancer, thankfully, slightly less common seen in thirteen patients in this cohort.
Ten of those had ILD and three patients who didn't have ILD. When just looking at the basic demographics here, kind of as you'd expect, patients with ILD were more likely to be older. They're more likely to be men. They're more likely to be smokers. So all kind of known risk factors for ILD and all also known risk factors for lung cancer.
So one question with studies of this nature is always, is this just shared risk factors giving us these two conditions? But the authors in fairness have tried to control for that in, I would say, relatively complicated statistical methodology. So those rolling numbers give us an incidence rate of lung cancer in patients with RA ILD of one point one three per one hundred patient years. And in those without ILD, but who still have RA of zero point one two per one hundred patient years. They then looked at this in two main ways.
The first was inverse probability of treatment weighting propensity score analysis methodology. That gave us an adjusted incident ratio of seven point one for lung cancer in patients who had RA LD compared to those with just RA. So that was quite high. There are relatively large confidence intervals on this being generated by relatively small numbers of patients who had lung cancer. So it went from one point four eight to thirty four point zero seven.
So it's hard to get an exact estimate, but certainly significantly more common in patients with ILD. They then went on and did another analysis, competing risk analysis, and that kind of confirmed the same findings. The hazard ratio here was 8.13. Again, confidence intervals are low slightly less, so going from 2.43 to 27.16. So that is giving us relatively clear evidence here that these patients are more likely to get lung cancer and that we should be on lookout for it.
I guess there is always the possibility of bias around testing here. Patients with ILD will generally be under relatively closer follow-up. They'll be seen quite possibly by a respiratory physician, as well as a rheumatologist. They may be getting serial CT scans, which of course will identify lung cancer at an earlier stage. So there's the possibility here that we're picking up more lung cancers either because we're seeing them earlier and they haven't yet been diagnosed in the RA population, or that we are seeing them because we're doing more testing and we're picking up lung cancers that would never have been a clinically significant problem.
I don't have a good feel for how true that is in lung cancer. It's obviously that happens a lot in things like prostate cancer, probably slightly less of a realistic explanation for lung cancer, which tends to be quite aggressive. So overall, I think this tells us we need to think about lung cancer in these patients. I'm not sure it would hugely change my clinical practice. I think obviously these patients were already on the lookout for their pulmonary outcomes and any change in their pulmonary status.
So I'm not sure it will hugely change what I do. Perhaps in that kind of relatively stable ILD population who may not be getting serial scans, I might start to think that maybe we should be doing them more frequently and delight my radiologists when I suggest they need to do more scans on these people as screening tests. So check out my Twitter at richardpaconway for more of my content from ACR twenty twenty six. And definitely check out RheumNow for all of the best in ACR twenty twenty six content. Hello, everyone.
I'm Richard Conway from Dublin, Ireland, reporting for RheumNow from ACR twenty twenty six. I'm here to talk to you today about an interesting poster from Sunday's poster session. This is abstract number four ninety. Was by who's at all from France I'm probably pronouncing that name wrong, so my apologies. My French is terrible.
The full title of this is the impact of coronary disease activity on pulmonary outcomes in OREO, the prospective cohorts translate to? I'm calling it the bad and maybe not so bad as we thought of disease activity in RA ILD. And this is an interesting study because it challenges something which has been a belief of mine, which is that disease activity is a bad thing in OREO in every way, that it makes OREO more likely to happen, that it makes it worse both in terms of progression and in terms of outcomes if that disease activity is ongoing in a patient with RA ILD. So these authors, this is a relatively large study and a relatively long study. So overall in this cohort, this translates to cohort, they have two seventy nine patients, two fifty eight of those were included in this analysis.
They follow-up out to a median of four years. And what they were looking at essentially is disease activity in different ways. But the easiest way to understand this was in comparing moderate high disease activity to the rest of the patients or those in low disease activity in remission. They measured up by DAS28C or P. And first, in terms of looking at outcomes, having moderate to high disease activity was associated with quite a significant increase in the risk of death or the need for lung transplantation.
So both relatively bad things, I would argue. And this held up in multivariable models with a multivariable hazard ratio of two point two eight. So definitely there a reason for us to think that controlling disease activity is good. They looked at ILD progression then, and that's when things got a bit more surprising. So they found progression in fifty percent of patients, which mean, that's giving us good power.
It's a good number of patients who are progressing here. And they found no significant association between DAS28 CRP and disease progression. And they looked at us in a variety of ways and still there really didn't seem to be any evidence of that. So to me, that really challenges my own thoughts about disease activity in RAILD and that patients and their progression is not inherently linked to the disease activity. And I'm not really sure how to explain that, and even more so how to explain that and tie that in with the other outcomes, seeing more deaths and lung transplants in those patients.
One thing we should think about is that not all patients progress irrespective of disease activity. So there can be a group of patients who are just kind of static in terms of ILD, but are not progressing, but are quite active in terms of disease activity. And I think it's equally true that there's another group of patients who have a very well controlled articular disease, but whose lungs are progressing. And I'm not so sure it's right to say that those patients do not have active disease. My own conceptualization of a lot of those patients is that they do have active rheumatoid disease.
They just don't have it in their joints. That that pulmonary process is still an active inflammatory process, often typified by ground glass infiltrates and inflammatory change on the CT. And I think maybe, again, our conceptualization of rheumatoid arthritis or rheumatoid disease is too joint based at times. And we shouldn't dismiss this ongoing lung disease as a potential indicator of oral activity. And then there's also the issue of those patients with fibrotic disease with a more clinical picture, more similar to IPF, who seem to be almost similar to what we see in IPF that the fibrosis itself could be causing progression of the fibrosis.
So there comes a tipping point with us where it's no longer disease activity, but it's the fibrotic response of the body, which is then generating progression. So I think lots of potential explanations here. I think it does challenge my own thoughts. I'm not so sure I dismiss these patients as being inactive in terms of overall rheumatoid activity, however. So follow me on Twitter at RichardPAConway for more content from ACR twenty twenty six, and check out all the best ACR twenty twenty six content at RheumNow.
This Room Now podcast is brought to you with support from Boehringer Ingelheim. Boehringer Ingelheim is committed to advancing research in rheumatology through ongoing work in progressive pulmonary fibrosis, interstitial lung disease, and systemic autoimmune rheumatic diseases, including systemic sclerosis, myositis, and beyond. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies in areas of high unmet medical need. Boehringer Ingelheim is proud to support RheumNow and the rheumatology community. Thank you for listening.
Hello, everyone. I'm Richard Conway from Dublin, Ireland reporting from ACR twenty twenty six for RheumNow. I'm here to talk to you today about an interesting poster from Sunday's poster session. This was abstract number four seventy. It was by Matute Gallardo and colleagues from Spain.
This was titled Treatment Patterns of Oral ILD Compared to Other Autoimmune ILDs. I'm calling it the real world of SARD ILD treatment. And I guess people are going to think I'm banging on about the same thing endlessly. But this interested me because it shows what rheumatologists in Spain, not in The US, but in Spain, do in practice and how that contrasts with the ACR, SARD, ILD guidelines. So just a way of background, the ACR guidelines recommend for rheumatoid arthritis related interstitial lung disease three first line therapies, but in order of preference, mycophenolate mofetil first, azathioprine second, rituximab third.
So these authors reported from their patient population about how these patients were actually treated in clinical practice. So they had patients with oral LD and patients with other rheumatic diseases associated with ILD. They had eighty five patients in total, thirty eight of those had rheumatoid arthritis related interstitial lung disease. So the non rheumatoid arthritis patients first sort of the usual stuff, systemic sclerosis, IPAF, some other autoimmune diseases associated with lung disease. And in that group, largely speaking, mycophenolate mofetol was the preferred option being seen for the various indications somewhere between seventy five percent, eighty five percent of patients were on mycophenolate.
So that kind of matches both the ACR guidelines for those diseases and matches what I do in clinical practice, and I think most rheumatologists do. But where the contrast came was with ORA ILD. So again, remember, ACR guidelines, mycophenolate number one, azatyper number two, rituximab number three. So first thing, I was delighted to see this. Ninety five percent of those RA patients were on methotrexate despite the fact that they had ILD.
So obviously there is confidence in the data that says it is safe and if anything may be beneficial to some extent in RAILD. And then when they got down into the advanced therapies, what they found, so patients on mycophenolate mofetil, zero. Patients on azathioprine, zero. Most commonly used medication, abatacept. Twenty six percent of patients on that.
Sixteen percent on rituximab, sixteen percent on tocilizumab, sixteen percent on nothing other than the methotrexate, which can be reasonable. And then the remainder were on a variety of JAK inhibitors and TNF inhibitors. So why do I like this abstract? I think, like anybody, I like when it supports your own clinical practice. And it seems that all those doubting thoughts that the ACR guidelines generate of, am I actually way out of sync with everyone is not true.
And that's in reality, most rheumatologists are managing rheumatoid arthritis related interstitial lung disease as I manage it, which is treating the rheumatoid arthritis with our best rheumatoid arthritis medications. And that is where we go. So I've been Richard Conway. Follow me on Twitter at RichardPAconway for more from ACR twenty twenty six from me, and check out RheumNow for all the best ACR twenty twenty six coverage.
Hello. My name is Elena Jerns. I'm reporting live from Orlando, Florida, ACR twenty twenty six. I want to talk to you about the session on autoimmune ILD that I saw today. It was fantastic.
It was delivered by a pulmonologist, Doctor. Zaman from Cedars Sinai and Doctor. Castellino from MassGen Hospital. They talked about a few things, what we really want from autoimmune ILD, and I just really loved how they delivered that. First, they emphasized what physicians treating autoimmune ILD really want from the drugs and from the studies.
First, many of the new drugs, many of the recent new drugs are being advertised that they're great because they slow down the rate of decline of ILD. I mean, is great. Nobody argues about that. But the excitement of that slowing down really comes from the data on idiopathic pulmonary fibrosis, but the disease is really relentless and, like, we expect it to progress. But the goals in SARDA ILD can be very different.
We actually want SARDA ILD to improve. We don't want merely stabilization or attenuation of the lung function decline. The reason for that is a ton of SARD ILD is inflammatory. We can argue that all of it is inflammatory because we have a SARD, right? Something like myositis ILD, for example.
The patient may decline fast and then stabilize, usually with the help of steroids, but we would strive to bring back the lung function with immunosuppressants or maybe a combination of drugs that include immunosuppressants. The session even presented some data that fibrotic looking ILD, like our radio ILD with usual interstitial pneumonia pattern, might at the very least stabilize with immunosuppression, even though oftentimes we hear that, Oh, these patients just need anti fibrotic. They probably need immunosuppressants as well. So takeaway point for that is that we can and we should strive for improvement in SART ILD. The session also emphasized the gap in autoimmune ILD studies, and I think that's a big one.
Many medications, especially the newer ones, have focused on progressive pulmonary fibrosis, but SARD ILD might not necessarily fall into that, at least not in the timeframe that a lot of those studies use as inclusion criteria. So we don't always know if the results of those studies are applicable to our patients with SAARD ILD. Also the outcomes that those studies have focused on really have been reduction in FVC decline, but as we talked about, some SAARDA ILD will not necessarily have that FVC decline. It might not be as relevant, you know, and also SAARDA ILD may not follow a linear course like a lot of patients with idiopathic pulmonary fibrosis can. So again, not super relevant.
And we are often left confused about whether to treat SAARD ILD that is not progressive, and what we should hope for. We don't really often know that from the results of the studies. And I think that lecture emphasized that we need more studies that enroll all comers of SARDA ILD, and also with outcomes that really focus on many aspects of the disease, and also the ILD of the disease and patient outcomes, because sometimes we can help the patient with those even if we don't necessarily improve the numbers on pulmonary function tests. But we need to prove that. So my takeaway point is that design studies of ILD that include non progressive fibrosis and power for improvement.
And the third takeaway point is that rheumatologists should be actively involved in SARD ILD management. Our patients with SARD ILD have many aspects to their disease that we need to balance the treatment for each of them against others and also against the risk for infection. We have so many drugs luckily that can help with many manifestations of that disease, but sometimes one that is more effective for one may not be as effective for others, so we still end up combining them. And this is complicated and it requires careful rheumatological expertise, so we should not leave the SARD ILD to the pulmonologist even though they're of course wonderful and many of them can treat SARD ILD just fine, but SARD ILD is more than just ILD. In SARD, in rheumatology, we need to treat the whole patient and all the extrapulmonary manifestations.
And we as rheumatologists should be well versed in drugs that can help the whole patient while helping the lungs. I guess a takeaway point is that SARTA LD is a team sport. If we were to go with soccer analogy, which I don't play soccer at all even, but I would say that a rheumatologist may take more the role of the offense with kind of just putting all those drugs out there, and the pulmonologist may be more like a goalie and kind of making sure that the lungs don't fall through the cracks. Thank you.
Hello, everyone. I'm Richard Conway from Dublin, Ireland. I'm reporting from ACR twenty twenty six for RheumNow. I'm here to talk to you today about an abstract that was presented at Monday's abstract session. And this is an ILD abstract, but I think maybe some ILD people will not have encountered it as was presented in the epidemiology and public health abstract session and not the rheumatoid abstract session.
This is by Kim et al from Korea. And the proper title of this is Lung Cancer Risk in RA and RA A risk analysis. I've called it RA A, and lung cancer. I think that's, does what it says on the tin, that's what it's about. This is a single center cohort, relatively large numbers of patients, however, six sixty four rheumatoid arthritis patients, two thirty of those had ILD, which is a lot.
That is more than a third of their patients. So it seems ILD is quite common in Korea. So that was one of the things they were looking at. And the other thing was lung cancer. Lung cancer, thankfully, slightly less common seen in thirteen patients in this cohort.
Ten of those had ILD and three patients who didn't have ILD. When just looking at the basic demographics here, kind of as you'd expect, patients with ILD were more likely to be older. They're more likely to be men. They're more likely to be smokers. So all kind of known risk factors for ILD and all also known risk factors for lung cancer.
So one question with studies of this nature is always, is this just shared risk factors giving us these two conditions? But the authors in fairness have tried to control for that in, I would say, relatively complicated statistical methodology. So those rolling numbers give us an incidence rate of lung cancer in patients with RA ILD of one point one three per one hundred patient years. And in those without ILD, but who still have RA of zero point one two per one hundred patient years. They then looked at this in two main ways.
The first was inverse probability of treatment weighting propensity score analysis methodology. That gave us an adjusted incident ratio of seven point one for lung cancer in patients who had RA LD compared to those with just RA. So that was quite high. There are relatively large confidence intervals on this being generated by relatively small numbers of patients who had lung cancer. So it went from one point four eight to thirty four point zero seven.
So it's hard to get an exact estimate, but certainly significantly more common in patients with ILD. They then went on and did another analysis, competing risk analysis, and that kind of confirmed the same findings. The hazard ratio here was 8.13. Again, confidence intervals are low slightly less, so going from 2.43 to 27.16. So that is giving us relatively clear evidence here that these patients are more likely to get lung cancer and that we should be on lookout for it.
I guess there is always the possibility of bias around testing here. Patients with ILD will generally be under relatively closer follow-up. They'll be seen quite possibly by a respiratory physician, as well as a rheumatologist. They may be getting serial CT scans, which of course will identify lung cancer at an earlier stage. So there's the possibility here that we're picking up more lung cancers either because we're seeing them earlier and they haven't yet been diagnosed in the RA population, or that we are seeing them because we're doing more testing and we're picking up lung cancers that would never have been a clinically significant problem.
I don't have a good feel for how true that is in lung cancer. It's obviously that happens a lot in things like prostate cancer, probably slightly less of a realistic explanation for lung cancer, which tends to be quite aggressive. So overall, I think this tells us we need to think about lung cancer in these patients. I'm not sure it would hugely change my clinical practice. I think obviously these patients were already on the lookout for their pulmonary outcomes and any change in their pulmonary status.
So I'm not sure it will hugely change what I do. Perhaps in that kind of relatively stable ILD population who may not be getting serial scans, I might start to think that maybe we should be doing them more frequently and delight my radiologists when I suggest they need to do more scans on these people as screening tests. So check out my Twitter at richardpaconway for more of my content from ACR twenty twenty six. And definitely check out RheumNow for all of the best in ACR twenty twenty six content. Hello, everyone.
I'm Richard Conway from Dublin, Ireland, reporting for RheumNow from ACR twenty twenty six. I'm here to talk to you today about an interesting poster from Sunday's poster session. This is abstract number four ninety. Was by who's at all from France I'm probably pronouncing that name wrong, so my apologies. My French is terrible.
The full title of this is the impact of coronary disease activity on pulmonary outcomes in OREO, the prospective cohorts translate to? I'm calling it the bad and maybe not so bad as we thought of disease activity in RA ILD. And this is an interesting study because it challenges something which has been a belief of mine, which is that disease activity is a bad thing in OREO in every way, that it makes OREO more likely to happen, that it makes it worse both in terms of progression and in terms of outcomes if that disease activity is ongoing in a patient with RA ILD. So these authors, this is a relatively large study and a relatively long study. So overall in this cohort, this translates to cohort, they have two seventy nine patients, two fifty eight of those were included in this analysis.
They follow-up out to a median of four years. And what they were looking at essentially is disease activity in different ways. But the easiest way to understand this was in comparing moderate high disease activity to the rest of the patients or those in low disease activity in remission. They measured up by DAS28C or P. And first, in terms of looking at outcomes, having moderate to high disease activity was associated with quite a significant increase in the risk of death or the need for lung transplantation.
So both relatively bad things, I would argue. And this held up in multivariable models with a multivariable hazard ratio of two point two eight. So definitely there a reason for us to think that controlling disease activity is good. They looked at ILD progression then, and that's when things got a bit more surprising. So they found progression in fifty percent of patients, which mean, that's giving us good power.
It's a good number of patients who are progressing here. And they found no significant association between DAS28 CRP and disease progression. And they looked at us in a variety of ways and still there really didn't seem to be any evidence of that. So to me, that really challenges my own thoughts about disease activity in RAILD and that patients and their progression is not inherently linked to the disease activity. And I'm not really sure how to explain that, and even more so how to explain that and tie that in with the other outcomes, seeing more deaths and lung transplants in those patients.
One thing we should think about is that not all patients progress irrespective of disease activity. So there can be a group of patients who are just kind of static in terms of ILD, but are not progressing, but are quite active in terms of disease activity. And I think it's equally true that there's another group of patients who have a very well controlled articular disease, but whose lungs are progressing. And I'm not so sure it's right to say that those patients do not have active disease. My own conceptualization of a lot of those patients is that they do have active rheumatoid disease.
They just don't have it in their joints. That that pulmonary process is still an active inflammatory process, often typified by ground glass infiltrates and inflammatory change on the CT. And I think maybe, again, our conceptualization of rheumatoid arthritis or rheumatoid disease is too joint based at times. And we shouldn't dismiss this ongoing lung disease as a potential indicator of oral activity. And then there's also the issue of those patients with fibrotic disease with a more clinical picture, more similar to IPF, who seem to be almost similar to what we see in IPF that the fibrosis itself could be causing progression of the fibrosis.
So there comes a tipping point with us where it's no longer disease activity, but it's the fibrotic response of the body, which is then generating progression. So I think lots of potential explanations here. I think it does challenge my own thoughts. I'm not so sure I dismiss these patients as being inactive in terms of overall rheumatoid activity, however. So follow me on Twitter at RichardPAConway for more content from ACR twenty twenty six, and check out all the best ACR twenty twenty six content at RheumNow.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.